Ardelyx, Inc. (ARDX)
After hours:
| Previous close | 7.79 |
| Open | 7.79 |
| Bid | 7.80 x 3400 |
| Ask | 7.83 x 2500 |
| Day's range | 7.69 - 7.86 |
| 52-week range | 3.16 - 10.13 |
| Volume | |
| Avg. volume | 5,784,004 |
| Market cap | 1.827B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.95 |
GlobeNewswireArdelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, now underway in Long Beach,
- GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 6, 2024, the compensation committee of the company’s board of directors granted 26 new non-executive employees options to purchase an aggregate of 511,500 shares of the company’s common stock, and granted 32 new non-executi
- GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to
